AmgenvsPACS

AMGN and PACS stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$443.89

Value $239B

-3.07%
AMGN's page

PACS

PACS Group, Inc.

$46.30

Value $7.3B

-4.63%
PACS's page

Amgen (AMGN) has a market value of $239B and PACS (PACS) $7.3B. Over the last year, with dividends, AMGN moved +33.5% and PACS +194.9%. The P/E is 25.5 for AMGN and 26.2 for PACS. Dividend yield: AMGN 2.24%, PACS none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$239B

    PACS$7.3B

    AMGN is 33 times PACS

  • Revenue, 12 months

    AMGN$38.9B

    PACS$5.7B

    AMGN is 6.8 times PACS

  • Net income, 12 months

    AMGN$9.4B

    PACS$278M

    AMGN is 34 times PACS

  • Operating margin

    AMGN32.4%

    PACS7.4%

    25.0 points apart

  • ROIC

    AMGN16.2%

    PACS22.9%

    6.7 points apart

  • P/E

    AMGN25.5

    PACS26.2

    About the same

  • Dividend yield

    AMGN2.2%

    PACS0.0%

    2.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+33.5%

PACS+194.9%

100200300DecFebAprJunAugOct
Returns by period
PeriodAMGNWith dividendsPACSWith dividends
1 year since November 17, 2025+33.5%Price +29.9%+194.9%Price +194.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenPACSPACS

Valuation

AMGNPACS
Valuation
Price$443.89$46.30
Market value$239B$7.3B
Enterprise value (EV)$280B$7.5B
P/E25.526.2
P/E, 5-year median23.0–
P/B16.76.0
EV/EBIT22.217.7
Free cash flow yield4.0%6.2%

Results and growth

AMGNPACS
Results and growth
Revenue, 12 months$38.9B$5.7B
Net income, 12 months$9.4B$278M
Free cash flow, 12 months$9.6B$448M
Earnings per share, 12 months$17.25$1.76
Revenue growth, year on year10.0%29.4%
Revenue growth a year, past+7.6%over 5 years+30.1%over 3 years
EPS growth a year, past+2.9%over 5 years+1.4%over 3 years

Margins and returns on capital

AMGNPACS
Margins and returns on capital
Gross margin70.9%23.8%
Operating margin32.4%7.4%
Net margin24.1%4.9%
ROIC16.2%22.9%
ROE87.8%26.8%

Balance sheet

AMGNPACS
Balance sheet
Cash$13.2B$115M
Total debt$54.0B$3.4B
Net debt / EBITDA2.3–
Interest cover4.8×16.2×

Dividends and buybacks

AMGNPACS
Dividends and buybacks
Dividend yield2.2%–
Dividend per share, 12 months$9.94–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield––
Shareholder yield2.2%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or PACS

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or PACS?

By market value, Amgen ($239B) is about 32.9 times PACS ($7.3B), at today's prices.

How did AMGN and PACS stock do over the last 1 years?

Since November 17, 2025, AMGN's price moved +29.9% and PACS's +194.9%. With dividends: AMGN +33.5% (+33.5% a year), PACS +194.9% (+194.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or PACS?

The dividend yield at today's price is 2.24% for Amgen and none for PACS. Over the last twelve months they paid $9.94 and – per share.

What is the P/E of AMGN and PACS?

At today's price, the P/E is 25.5 for AMGN and 26.2 for PACS. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Amgen or PACS?

Over the last twelve months, the net margin was 24.1% for Amgen and 4.9% for PACS, and the operating margin 32.4% and 7.4%. Revenue was $38.9B and $5.7B.

Which is the better investment, Amgen or PACS?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.